Novo Nordisk and Flagship Pioneering, a life science venture capital firm based in the US, have struck a deal concerning the latter’s life science portfolio of firms, a joint press release has announced.
The portfolio, which Flagship describes as a ”bioplatform,” consists of 41 companies and will be leveraged to create research programs within cardiometabolic and rare diseases.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.